COMMUNIQUÉS West-GlobeNewswire

H1 25 Results Confirm the Relevance of Roquette’s Strategy
25/09/2025
H1 25 Results Confirm the Relevance of Roquette’s Strategy Roquette outperforms its key markets, delivering solid H1 results in current complex market conditions. Successful completion of the acquisition of IFF Pharma [...]
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
25/09/2025
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public [...]
Summary Notice of Proposed Settlement of Derivative Actions
25/09/2025
LEHI, Utah, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Owlet, Inc. (NYSE:OWLT) has released the following notice: IN THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA IN RE OWLET, INC. SHAREHOLDER [...]
MBX Biosciences Announces Pricing of Upsized Public Offering
25/09/2025
CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]
Range Impact Announces $550,000 Capital Raise
24/09/2025
Cleveland, Ohio, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in [...]
Verano to Report Third Quarter 2025 Financial Results on October 29, 2025
24/09/2025
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury
24/09/2025
Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical [...]
Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025
24/09/2025
GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
uniQure Announces $200 Million Proposed Public Offering
24/09/2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
24/09/2025
GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) [...]
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
24/09/2025
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary [...]
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
24/09/2025
Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory [...]
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
24/09/2025
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of [...]
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
24/09/2025
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. [...]
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
24/09/2025
- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory [...]
CROSSJECT présente ses résultats financiers et les principaux faits marquants pour le premier semestre 2025
24/09/2025
Communiqué de presse CROSSJECT présente ses résultats financiers et les principaux faits marquants pour le premier semestre 2025 Position de trésorerie : 6.3 millions d'euros, contre 7,0 millions d’euros au 31 décembre [...]
CROSSJECT presents its financial results and key highlights for the first half of 2025
24/09/2025
Press release CROSSJECT presents its financial results and key highlights for the first half of 2025 Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the Company's excellent [...]

Pages